You just read:

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

News provided by

Impel NeuroPharma

Jan 06, 2019, 10:00 ET